Why the study?
Does a single low i.v. dose of aspirin reduce transient ischemic episodes in patients with vasospastic angina?
Does a single low i.v. dose of aspirin reduce transient ischemic episodes in patients with vasospastic angina?
Thromboxane A2 blockade with low-dose aspirin does not prevent attacks of vasospastic angina, suggesting platelet TxA2 is not responsible for initiating coronary vasospasm.
Answers are grounded in this paper and cite their sources.
Low-dose aspirin showed no effect on ischemic episodes in vasospastic angina; hypothesis-generating that platelet TxA2 does not initiate spasm.
Thromboxane A2 (TxA2), released by aggregating platelets, has been proposed as a potential mediator of coronary vasospasm. We studied six patients with variant angina, a clinical syndrome due to coronary vasospasm, and one patient with frequent recurrent episodes of transient ST-segment depression at rest in whom the spasm was demonstrated angiographically. All patients underwent continuous ECG monitoring for 2 days before and 2 days after a single, low, i.v. dose of aspirin (2 mg/kg), which reduced TxB2 (the stable metabolite of TxA2) to less than 3% of the control values. There were 129 transient ischemic episodes during control and 146 after aspirin, when platelet TxB2 was reduced to negligible levels. The duration, severity and incidence of symptomatic episodes were not significantly affected by TxA2 blockade. We conclude that platelet TxA2 is probably not responsible for the initiation of coronary vasospasm.
No takes yet. Share an insight, caveat, or question.
Chierchia et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: